Case report: cystic fibrosis, lung transplantation, and the novel H1N1 flu.
The H1N1 pandemic flu is a significant risk factor for both patients with chronic disease who need organ transplantation and transplant recipients. This population needs special care regarding comorbidities and related complications. MB, a 38-year-old Italian cystic fibrosis male patient with lung and pancreatic involvement, was referred to our division in July 2009 for fever-associated arthromyalgia, headache, and rhinitis. Lung transplantation had been performed in September 2005, and he was subsequently treated with immunosuppressive therapy: tacrolimus, everolimus, and prednisolone. In the past, chronic respiratory colonization with Pseudomonas aeruginosa and intermittent infection with Aspergillus flavus, chronic renal failure, hypertension, and diabetes mellitus complicated his clinical history. He started antiviral treatment with oseltamivir despite no travel history and no respiratory symptoms. H1N1 swab was positive. Three days later, the patient was admitted to the hospital for the persistence of fever and the onset of cough. Chest x-ray showed a left lower pneumonia, which was confirmed by computerized tomography. Broad-spectrum antibiotic therapy led to an improvement of the clinical condition. The patient was discharged 8 days later; a control swab was negative. This case report suggests some general considerations regarding solid organ recipients: 1) Flu-related complications require early treatment (both antiviral and antibiotic); 2) active microbiologic surveillance is important to prevent lethal infections (ie, invasive aspergillosis); 3) evaluation of immunosuppressant blood levels is necessary for drug-drug interactions. Active prevention is the best option for decreasing morbidity and mortality in the transplanted patient.
Bresci
S
S
Infectious Disease Department, Careggi University and Hospital, Firenze, Italy. biba28@libero.it
Borchi
B
B
Ambu
S
S
Taccetti
G
G
Braggion
C
C
Leoncini
F
F
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000150:complications / Q000000981:diagnostic imaging / Q000601:surgery*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D053118:Influenza A Virus, H1N1 Subtype / Q000302:isolation & purification*; D007251:Influenza, Human / Q000150:complications* / Q000000981:diagnostic imaging; D016040:Lung Transplantation / Q000276:immunology; D008297:Male; D000077731:Meropenem; D053139:Oseltamivir / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000150:complications / Q000601:surgery; D011550:Pseudomonas aeruginosa; D013902:Radiography, Thoracic; D016559:Tacrolimus / Q000627:therapeutic use; D013845:Thienamycins / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D013845:Thienamycins; D053139:Oseltamivir; D002939:Ciprofloxacin; D000077731:Meropenem; D016559:Tacrolimus